AIA
SUPN icon

Alera Investment Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Alera Investment Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-21
Closed -$1K – 877
2019
Q1 		$1K Hold
21
– – ﹤0.01% 1067
2018
Q4 		$1K Buy
+21
New +$903 ﹤0.01% 1015

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Alera Investment Advisors's SUPN Position: Q2 2019 in Review

Alera Investment Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 21 shares — an estimated $1K sold.

Alera Investment Advisors first reported a position in SUPN in Q4 2018 and held it in 2 quarters. The position peaked at $1K in Q1 2019. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

  • Alera Investment Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Alera Investment Advisors sold 21 Supernus Pharmaceuticals shares in Q2 2019, an estimated $1K.
  • Alera Investment Advisors first reported a position in Supernus Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Alera Investment Advisors's Supernus Pharmaceuticals position peaked at $1K in Q1 2019.
  • 272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on Alera Investment Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.